(c) if so, what are the reasons for which show cause notice has not been issued to the producer;

(d) what steps have been taken to fix the responsibility on the bureaucrats who have enabled the company to overcharge the prices; and

(e) by when the prices of these products would be fixed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) to (e) Dexona tablets based on bulk drug Dexamethasone are produced by M/s. Cadila Labs. Ltd. A price of Rs. 73.96 (exclusive of excise duty) was notified under DPCO, 1979 for 100's pack of this formulation on 19-6-1982. The details of price fixed for Dexona Eye/Ear solution under DPCO, 1987 are given below :—

Name of the product	Pack size	Maximum Retail price (Rs.)	Date
Dexona Eye/Ear Solution	2.5ml vial	3.74	12-7-88

Recovery in Respect of Dipyridamol

4586. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 649 given in the Rajya Sabha on 1st August, 1988 and state:

(a) when the notice for recovery of Rs. 59.95 lakhs in respect of Dipyridamol was issued;

(b) whether this recovery has been cleared by the Law Ministry; if so, when was this clearance given; and

(c) what prevented his Ministry in writing to the Collector for the recovery of the amount as arrears of land revenue?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) Notice for recovery of Rs. 59.95 lakhs in respect of Dipyridamol was issued in May, 1986;

(b) The law Ministry was consulted in regard to the provisions contained in para 7(2) of DPCO, 1979 in March, 1986.

(c) The amount calculated for recovery has been disputed by the company.

Production of Hydrocortisone

4587. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state :

(a) what is the approved capacity and production of Hydrocortisone in the country during the last three years yearwise;

(b) what were the imports and CIF import prices of this drug during the last three years, yearwise;

(c) what is the sales turnover of Hydrocortisone eye preparations and Dexamethasone and Hetamethasone eye preparations as per ORG purchased by his Ministry out of Government Fund; and

(d) on what basis the eye preparations of Hydrocortisone are in Catagory-I and eye preparations of other corticosteroids are in Category-II?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) To the extent information is available the approved capacity for Hydrocortisone is 361 Kgs. Production of this item is not monitored by this Ministry.

(b) Details of imports are published in the "Monthly Statistics for foreign trade in India", Vol. II, Copies of which are available in the Parliament Library.

(c) Sales turnover of formulations is not monitored.

(d) Eye preparations of Hydrocortisone have been included in Category-I, as per the recommendations of Ministry of Health and Family Welfare whereas eye preparations of other Corticosteroids have been included in Category-II, on the recommendations of Kelkar Committee.

Bulk Drugs for Flucort Range Formulations

4588. SHRI DHARANIDHAR BASUMATARI: Will the Miniser of INDUSTRY be pleased to refer to the answer to Unstarred Question 3289 given in the Rajya Sabha on 22nd August, 1988 and state:

(a) what is the name of the bulk drug on which Flucort range of formulations are based;

(b) what is the CIF price of this drug;

(c) what was the estimated all India sales turnover during 1986 of Flucort range of formulations according to ORG being subscribed by his Ministry;

(d) what is the exclusion criteria on which this drug was excluded from price control by Kelkar Committee; and

(e) what was the price of each Flucort formulations under DPCO, 1979, their present price and the percentage change in each case?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Flucort range of formulations are based on bulk drug Flucinolone acetonide.

(b) The required details to the extent available are given in the Statement (*See* below).

(c) Sales turnover is not monitored.

(d) The Kelkar Committee adopted following five criteria of excluding the drugs.

(i) Exclude those drugs which are not produced in India, provided that the consumption is not significant either now or in the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.

(iii) To exclude all new drugs for which process of manufacture were developed in-